Mirati Therapeutics, Inc. (MRTX): Product News News

MRTX – Company is reprioritizing its development programs to capitalize on encouraging data and development opportunities in its sitravatinib and KRAS programs… will de-prioritize further investment in glesatinib and will pursue opportunities to partner the program.


Key Facts Surrounding This News Item


  • MRTX had a POWR Rating of B (Buy) coming into today.
  • MRTX was 10.18% above its 10-Day Moving Average coming into today.
  • MRTX was 8.52% above its 20-Day Moving Average coming into today.
  • MRTX was 29.42% above its 50-Day Moving Average coming into today.
  • MRTX was 85.72% above its 100-Day Moving Average coming into today.
  • MRTX was 137.61% above its 200-Day Moving Average coming into today.
  • MRTX had returned +216.84% year-to-date leading up to today’s news, versus a +17.11% return from the benchmark S&P 500 during the same period.

More Info About Mirati Therapeutics, Inc. (MRTX)


Mirati Therapeutics develops molecularly targeted cancer treatments that are intended to inhibit tumor growth. The company was founded in 1995 and is based in San Diego, California. View our full MRTX ticker page with ratings, news, and more.

MRTX at a Glance

MRTX Current POWR Rating™
Overall POWR Rating™
MRTX Current Price $17.25 9.21%
More MRTX Ratings, Data, and News

MRTX Price Reaction

The day of this event (Nov. 13, 2017)
MRTX Closing Price$15.50 2.99%
MRTX Volume390,500
18.47% from avg
Leading up to this event
MRTX 1-mo return4.51%
After this event
MRTX 1-day return14.02%
MRTX 3-day return20.79%

MRTX Price Chart



More Mirati Therapeutics, Inc. (MRTX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All MRTX News
Page generated in 0.7358 seconds.